Bio-Rad at CLSAupgraded to Outperform from Underperform at CLSA

theflyonthewall.com

CLSA upgraded Bio-Rad based on earnings leverage, consistent diagnostics growth, ERP completion, easier currency comps, and exposure to Asia. Price target raised to $124 form $103.

View Comments (0)